ArticleFrontiers in pharmacology2026
Haikunshenxi capsule alleviates renal fibrosis in chronic kidney disease via modulation of indoxyl Sulfate-Aryl hydrocarbon receptor signaling.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Renal fibrosis, a common pathological endpoint in Chronic Kidney Disease (CKD), is closely associated with the accumulation of gut-derived uremic toxins, underscoring the therapeutic relevance of the gut-kidney axis. This study investigated the antifibrotic mechanism of Haikunshenxi Capsule (HKSX), a marine-derived drug, and its principal plant-derived metabolite, fucoidan (FPS), focusing on the Indoxyl Sulfate (IS)-Aryl Hydrocarbon Receptor (AhR) signaling pathway. Methods: In an adenine-induced CKD rat model, HKSX treatment significantly improved renal function and attenuated tubulointerstitial fibrosis. Targeted metabolomics analysis revealed that HKSX modulated tryptophan metabolism and reduced the systemic IS accumulation. Mechanistically, immunofluorescence and Western blotting revealed that the elevated IS levels were associated with increased Results: HKSX treatment reduced Conclusion: In conclusion, HKSX exerts a renal protective effect by reducing systemic uremic toxin accumulation and attenuating IS/AhR signaling-associated EMT, supporting the therapeutic potential of HKSX against renal fibrosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.